TY - JOUR
T1 - Pharmacological therapies and drug development targeting SARS-CoV-2 infection
AU - Jiang, Yizhou
AU - Rubin, Limor
AU - Zhou, Zhiwei
AU - Zhang, Haibo
AU - Su, Qiaozhu
AU - Hou, Sheng Tao
AU - Lazarovici, Philip
AU - Zheng, Wenhua
N1 - Publisher Copyright:
© 2022
PY - 2022/12
Y1 - 2022/12
N2 - The development of therapies for SARS-CoV-2 infection, based on virus biology and pathology, and of large- and small-scale randomized controlled trials, have brought forward several antiviral and immunomodulatory drugs targeting the disease severity. Casirivimab/Imdevimab monoclonal antibodies and convalescent plasma to prevent virus entry, Remdesivir, Molnupiravir, and Paxlovid nucleotide analogs to prevent viral replication, a variety of repurposed JAK-STAT signaling pathway inhibitors, corticosteroids, and recombinant agonists/antagonists of cytokine and interferons have been found to provide clinical benefits in terms of mortality and hospitalization. However, current treatment options face multiple clinical needs, and therefore, in this review, we provide an update on the challenges of the existing therapeutics and highlight drug development strategies for COVID-19 therapy, based on ongoing clinical trials, meta-analyses, and clinical case reports.
AB - The development of therapies for SARS-CoV-2 infection, based on virus biology and pathology, and of large- and small-scale randomized controlled trials, have brought forward several antiviral and immunomodulatory drugs targeting the disease severity. Casirivimab/Imdevimab monoclonal antibodies and convalescent plasma to prevent virus entry, Remdesivir, Molnupiravir, and Paxlovid nucleotide analogs to prevent viral replication, a variety of repurposed JAK-STAT signaling pathway inhibitors, corticosteroids, and recombinant agonists/antagonists of cytokine and interferons have been found to provide clinical benefits in terms of mortality and hospitalization. However, current treatment options face multiple clinical needs, and therefore, in this review, we provide an update on the challenges of the existing therapeutics and highlight drug development strategies for COVID-19 therapy, based on ongoing clinical trials, meta-analyses, and clinical case reports.
KW - Clinical trials
KW - COVID-19
KW - Cytokine storm
KW - Drugs in clinic
KW - Drugs in development
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85140727841&partnerID=8YFLogxK
U2 - 10.1016/j.cytogfr.2022.10.003
DO - 10.1016/j.cytogfr.2022.10.003
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 36266222
AN - SCOPUS:85140727841
SN - 1359-6101
VL - 68
SP - 13
EP - 24
JO - Cytokine and Growth Factor Reviews
JF - Cytokine and Growth Factor Reviews
ER -